Literature DB >> 2889962

Is cytomegalovirus interstitial pneumonitis in transplant recipients an immunopathological condition?

J E Grundy1, J D Shanley, P D Griffiths.   

Abstract

The conventional explanation for the high fatality rate due to cytomegalovirus (CMV) pneumonitis among allogeneic transplant recipients is that immunosuppression renders the host unable to control replication of this opportunistic agent. However, evidence from studies in man and the murine model of CMV show that virus replication in the lung is unrelated to the development of pathological effects, and that a host immune response is required for the induction of pneumonitis. Thus the hypothesis is that limited CMV replication in the lungs leads to display of a virus-coded protein, which is recognised by host T-cells, and that the pneumonitis is due to an uncontrolled accumulation and recruitment of such cells in the lungs. The reason why CMV is found in the lungs of patients with the acquired immunodeficiency syndrome (AIDS) without producing pneumonitis is probably because these patients cannot mount the pathogenic T-cell response. According to the hypothesis stated here, if the immune capabilities of AIDS patients can be restored, life-threatening CMV pneumonitis may develop.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2889962     DOI: 10.1016/s0140-6736(87)92560-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  54 in total

Review 1.  The immunocompromised patient and transfusion.

Authors:  K G Badami
Journal:  Postgrad Med J       Date:  2001-04       Impact factor: 2.401

2.  Enrichment of immediate-early 1 (m123/pp89) peptide-specific CD8 T cells in a pulmonary CD62L(lo) memory-effector cell pool during latent murine cytomegalovirus infection of the lungs.

Authors:  R Holtappels; M F Pahl-Seibert; D Thomas; M J Reddehase
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Quantification of cytomegalovirus in bronchoalveolar lavage fluid after allogeneic marrow transplantation by centrifugation culture.

Authors:  M A Slavin; C A Gleaves; H G Schoch; R A Bowden
Journal:  J Clin Microbiol       Date:  1992-11       Impact factor: 5.948

Review 4.  Diagnosis of cytomegalovirus infection: a review.

Authors:  D Pillay; P D Griffiths
Journal:  Genitourin Med       Date:  1992-06

5.  The pulmonary complications of bone marrow transplantation in adults.

Authors:  P W Noble
Journal:  West J Med       Date:  1989-04

Review 6.  AIDS and the lung: update 1992. 2. Recent developments in the management of the pulmonary complications of HIV disease.

Authors:  D M Mitchell; R F Miller
Journal:  Thorax       Date:  1992-05       Impact factor: 9.139

7.  Combined antibody and ganciclovir treatment of murine cytomegalovirus-infected normal and immunosuppressed BALB/c mice.

Authors:  R H Rubin; P Lynch; M S Pasternack; D Schoenfeld; D N Medearis
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

8.  Development of a high-throughput assay to measure the neutralization capability of anti-cytomegalovirus antibodies.

Authors:  Thomas J Gardner; Cynthia Bolovan-Fritts; Melissa W Teng; Veronika Redmann; Thomas A Kraus; Rhoda Sperling; Thomas Moran; William Britt; Leor S Weinberger; Domenico Tortorella
Journal:  Clin Vaccine Immunol       Date:  2013-02-06

9.  Human cytomegalovirus inhibits differentiation of monocytes into dendritic cells with the consequence of depressed immunological functions.

Authors:  Sara Gredmark; Cecilia Söderberg-Nauclér
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  Differential CMV-specific CD8+ effector T cell responses in the lung allograft predominate over the blood during human primary infection.

Authors:  Matthew R Pipeling; Erin E West; Christine M Osborne; Amanda B Whitlock; Lesia K Dropulic; Matthew H Willett; Michael Forman; Alexandra Valsamakis; Jonathan B Orens; David R Moller; Noah Lechtzin; Stephen A Migueles; Mark Connors; John F McDyer
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.